LTC1912640I2 - HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui - Google Patents

HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui

Info

Publication number: LTC1912640I2
Authority: LT; Lithuania
Prior art keywords: hdac inhibitor; myeloma treatment; inhibitor panobinostat; panobinostat; myeloma
Prior art date: 2005-08-03

Application number

LTPA2016003C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-03

Filing date

2016-01-22

Publication date

2017-09-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37307336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1912640(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-01-22 Application filed by Novartis Ag filed Critical Novartis Ag

2017-09-11 Publication of LTC1912640I2 publication Critical patent/LTC1912640I2/lt

Links

206010035226 Plasma cell myeloma Diseases 0.000 title 1
229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
239000003276 histone deacetylase inhibitor Substances 0.000 title 1
201000000050 myeloid neoplasm Diseases 0.000 title 1
FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 title 1
229960005184 panobinostat Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTPA2016003C 2005-08-03 2016-01-22 HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui LTC1912640I2 (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US70522605P	2005-08-03	2005-08-03
PCT/US2006/029801 WO2007019116A1 (en)	2005-08-03	2006-08-01	Use of hdac inhibitors for the treatment of myeloma

Publications (1)

Publication Number	Publication Date
LTC1912640I2 true LTC1912640I2 (lt)	2017-09-11

Family

ID=37307336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTPA2016003C LTC1912640I2 (lt)	2005-08-03	2016-01-22	HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui

Country Status (18)

Country	Link
US (2)	US20080221126A1 (lt)
EP (1)	EP1912640B1 (lt)
JP (2)	JP5665271B2 (lt)
KR (1)	KR101354237B1 (lt)
CN (2)	CN104324025A (lt)
AU (1)	AU2006278718B2 (lt)
BR (1)	BRPI0614090A2 (lt)
CA (1)	CA2617274C (lt)
DK (1)	DK1912640T3 (lt)
ES (1)	ES2545076T3 (lt)
HU (1)	HUE028025T2 (lt)
LT (1)	LTC1912640I2 (lt)
MX (1)	MX2008001610A (lt)
PL (1)	PL1912640T3 (lt)
PT (1)	PT1912640E (lt)
RU (1)	RU2420279C3 (lt)
SI (1)	SI1912640T1 (lt)
WO (1)	WO2007019116A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2420279C3 (ru) *	2005-08-03	2017-03-14	Новартис Аг	Применение ингибиторов hdac для лечения миеломы
US20100069458A1 (en) *	2007-02-15	2010-03-18	Peter Wisdom Atadja	Combination of lbh589 with other therapeutic agents for treating cancer
ES2726401T3 (es) *	2007-05-30	2019-10-04	Novartis Ag	Uso de inhibidores de HDAC para el tratamiento de la destrucción ósea
US20120046242A1 (en) *	2008-12-24	2012-02-23	Massachusetts Institute Of Technology	Molecular activators of the wnt/beta-catenin pathway
MX2012005560A (es) †	2009-11-13	2012-10-05	Receptos Inc	Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
BR112013004714A2 (pt) *	2010-09-01	2016-05-17	Novartis Ag	"combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
MA41544A (fr) *	2015-02-19	2017-12-26	Novartis Ag	Dosages de panobinostat pour le traitement du myélome multiple
JP6923219B2 (ja)	2015-11-03	2021-08-18	ホーホシューレダルムシュタット	選択的ｈｄａｃ８阻害剤およびこれらの使用
CN105348169B (zh) *	2015-11-16	2018-03-30	青岛大学	一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用
CN109705057B (zh) *	2017-10-25	2023-05-30	成都先导药物开发股份有限公司	组蛋白去乙酰化酶抑制剂及其制备方法与用途
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
JP2021530504A (ja)	2018-07-18	2021-11-11	ヒルストリーム・バイオファーマ・インコーポレイテッド	サリノマイシンを含む高分子ナノ粒子
WO2022251844A1 (en)	2021-05-25	2022-12-01	Hillstream Biopharma, Inc.	Polymeric nanoparticles comprising chemotherapeutic compounds and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2444867C (en) *	2001-05-16	2010-08-17	Novartis Ag	Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
AU2002361022A1 (en) *	2001-12-07	2003-06-17	Novartis Ag	Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
US20040132825A1 (en)	2002-03-04	2004-07-08	Bacopoulos Nicholas G.	Methods of treating cancer with HDAC inhibitors
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
MXPA05012464A (es) *	2003-05-21	2006-01-30	Novartis Ag	Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
CN102349927A (zh)	2003-08-29	2012-02-15	Hdac默克研究有限责任公司	联合治疗癌症的方法
US8999289B2 (en)	2005-03-22	2015-04-07	President And Fellows Of Harvard College	Treatment of protein degradation disorders
RU2420279C3 (ru) *	2005-08-03	2017-03-14	Новартис Аг	Применение ингибиторов hdac для лечения миеломы

2006
- 2006-08-01 RU RU2008107871A patent/RU2420279C3/ru not_active IP Right Cessation
- 2006-08-01 EP EP06789025.1A patent/EP1912640B1/en active Active
- 2006-08-01 MX MX2008001610A patent/MX2008001610A/es active IP Right Grant
- 2006-08-01 PL PL06789025T patent/PL1912640T3/pl unknown
- 2006-08-01 CA CA2617274A patent/CA2617274C/en active Active
- 2006-08-01 PT PT67890251T patent/PT1912640E/pt unknown
- 2006-08-01 CN CN201410610419.9A patent/CN104324025A/zh active Pending
- 2006-08-01 DK DK06789025.1T patent/DK1912640T3/en active
- 2006-08-01 CN CNA2006800281244A patent/CN101232880A/zh active Pending
- 2006-08-01 ES ES06789025.1T patent/ES2545076T3/es active Active
- 2006-08-01 BR BRPI0614090-4A patent/BRPI0614090A2/pt not_active Application Discontinuation
- 2006-08-01 WO PCT/US2006/029801 patent/WO2007019116A1/en not_active Ceased
- 2006-08-01 SI SI200631952T patent/SI1912640T1/sl unknown
- 2006-08-01 AU AU2006278718A patent/AU2006278718B2/en not_active Ceased
- 2006-08-01 US US11/996,323 patent/US20080221126A1/en not_active Abandoned
- 2006-08-01 HU HUE06789025A patent/HUE028025T2/en unknown
- 2006-08-01 KR KR1020087002803A patent/KR101354237B1/ko not_active Expired - Fee Related
- 2006-08-01 JP JP2008525092A patent/JP5665271B2/ja active Active
2010
- 2010-03-04 US US12/717,373 patent/US8883842B2/en active Active
2013
- 2013-04-04 JP JP2013078867A patent/JP5876435B2/ja active Active
2016
- 2016-01-22 LT LTPA2016003C patent/LTC1912640I2/lt unknown

Also Published As

Publication number	Publication date
JP5876435B2 (ja)	2016-03-02
US8883842B2 (en)	2014-11-11
JP5665271B2 (ja)	2015-02-04
CA2617274A1 (en)	2007-02-15
JP2013173757A (ja)	2013-09-05
EP1912640A1 (en)	2008-04-23
KR101354237B1 (ko)	2014-01-22
US20080221126A1 (en)	2008-09-11
RU2420279C2 (ru)	2011-06-10
RU2420279C3 (ru)	2017-03-14
CN101232880A (zh)	2008-07-30
DK1912640T3 (en)	2015-09-14
CA2617274C (en)	2017-10-10
KR20080031937A (ko)	2008-04-11
WO2007019116A1 (en)	2007-02-15
RU2008107871A (ru)	2009-09-10
MX2008001610A (es)	2008-02-19
PL1912640T3 (pl)	2015-11-30
SI1912640T1 (sl)	2015-10-30
AU2006278718A1 (en)	2007-02-15
CN104324025A (zh)	2015-02-04
HUE028025T2 (en)	2016-11-28
AU2006278718B2 (en)	2010-10-07
BRPI0614090A2 (pt)	2011-03-09
ES2545076T3 (es)	2015-09-08
EP1912640B1 (en)	2015-06-17
US20100160257A1 (en)	2010-06-24
JP2009503087A (ja)	2009-01-29
PT1912640E (pt)	2015-09-22

Publication	Publication Date	Title
LTC1912640I2 (lt)	2017-09-11	HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui
IL284991A (en)	2021-08-31	Antibodies against cd38 for treatment of multiple myeloma
DK1940839T3 (da)	2013-10-14	Pyridopyrimidione Inhibitors of P13Ka
BRPI0719204A2 (pt)	2014-03-04	Inibidores de hdac
ZA200801394B (en)	2009-12-30	Novel sulphonylpyrroles as inhibitors of HDAC S novel sulphonylpyrroles
SMAP200900058A (it)	2010-01-19	Composti e composizioni come inibitori di proteinachinasi
SM201000108B (it)	2012-01-18	Composti e composizioni come inibitori di proteinachinasi
SMAP200900020A (it)	2009-05-11	Composti e composizioni come inibitori di proteinachinasi
SMAP200900031A (it)	2009-07-14	Composti e composizioni come inibitori di proteinachinasi
EP2265590A4 (en)	2012-04-25	SELECTIVE HISTONDEACETYLASE HEMMER
EP1845849A4 (en)	2014-08-13	EXISCELET FOR THE LEGS
EP1874239A4 (en)	2011-08-24	HALF-POWERED EXOSCELETT OF LOWER EXTREMITY
ATE434620T1 (de)	2009-07-15	Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1981519A4 (en)	2010-01-06	PROTEASE INHIBITION
EP2272817A4 (en)	2011-12-14	PAI-1 INHIBITORS
EP1991226A4 (en)	2012-01-25	Histone deacetylase INHIBITORS
EP2068339A4 (en)	2012-02-29	Electron source
EP2010168A4 (en)	2011-06-01	Histone deacetylase INHIBITORS
ATE521238T1 (de)	2011-09-15	Kristalline modifikationen des pyraclostrobins
EP2229363A4 (en)	2010-12-15	Renin Inhibitors
PL2205720T3 (pl)	2017-06-30	Kompozycja do leczenia stwardnienia rozsianego
EP2124563A4 (en)	2011-04-20	Benzimidazole TRPV1 INHIBITORS
EP2231596A4 (en)	2012-06-06	INHIBITORS OF HISTONATE ACETYLASE
EP2036895A4 (en)	2010-12-22	HSP90 INHIBITOR
EP1940406A4 (en)	2009-11-18	POTASSIUM CHANNEL INHIBITORS